MFOHome About Commentary Discussions Funds The Best Resources Support Us!

Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Sign In Register

Categories

Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.

    Support MFO

  • Donate through PayPal

Early results from Moderna coronavirus vaccine trial show participants developed antibodies

LewisBraham
edited May 2020 in The OT Bullpen
https://cnn.com/2020/05/18/health/coronavirus-vaccine-moderna-early-results/index.html
If future studies go well, the company's vaccine could be available to the public as early as January, Dr. Tal Zaks, Moderna's chief medical officer, told CNN.
"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks said.
These early data come from the Phase 1 clinical trial, which typically studies a small number of people and focuses on whether a vaccine is safe and elicits an immune response.
Sign In or Register to comment.